Aadi Bioscience, Inc

Aadi Bioscience Inc.(Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). In March 2025, we became a wholly-owned subsidiary of KAKEN Pharmaceutical Co, Ltd, an R&D driven pharmaceutical company in Japan. A science-first mindset and patient-centric approach is always in our genes. Together with KAKEN, we continue to dedicate to developing products for cancers with mTOR pathway driver alterations. For more information, please visit: https://aadibio.com/ and